PHAT(Phathom Pharmaceuticals, Inc.) · 财务报表

PHAT(Phathom Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$0$682.00K$55.25M$175.11M
毛利润$0$515.00K$47.28M$152.51M
营业利润−$172.44M−$167.31M−$277.47M−$159.99M
净利润−$197.72M−$201.59M−$334.33M−$221.25M
经营现金流−$146.53M−$137.58M−$266.77M−$166.78M
自由现金流−$147.57M−$139.21M−$266.90M−$167.00M
摊薄每股收益$-5.05$-3.93$-5.29$-3.03

Phathom Pharmaceuticals, Inc. PHAT